Regolamento HTA: rilasciato il Report on Emerging Health Technologies

The Subgroup for the identification of emerging health technologies of the Coordination Group on Health Technology Assessment (the ‘HTACG’) released a report on Emerging Health Technologies.

This report highlights new and emerging health technologies that may be relevant for JCAs starting in 2026.

Key Points:

• The report identifies innovative medical products and technologies likely to be considered for future EU HTA evaluations.
• Three main categories are covered:
  1. Medicinal Products (Oncology): 61 products with new therapeutic indications for cancer, including 6 with EMA PRIME designation and 21 orphan drugs.
  2. Advanced Therapy Medicinal Products (ATMPs): 25 ATMPs with new indications, 8 with PRIME status, and 7 orphan drugs.
  3. Medical Devices: 15 devices have received scientific advice from EMA and may be relevant for joint assessments from 2026.
• The report includes graphics showing the distribution of products by indication and regulatory status.